A Review on the Interaction of Nucleoside Analogues with SARS-CoV-2 RNA Dependent RNA Polymerase

Overview

Journal Int J Biol Macromol

Publisher Elsevier

Date 2021 Mar 26

PMID 33766591

Citations 13

Authors

Suliman Khan

Farnoosh Attar

Samir Haj Bloukh

Majid Sharifi

Faisal Nabi

Qian Bai

Rizwan Hasan Khan

Mojtaba Falahati

Affiliations

Soon will be listed here.

Abstract

The outbreaks of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in 2019, have highlighted the concerns about the lack of potential vaccines or antivirals approved for inhibition of CoVs infection. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) which is almost preserved across different viral species can be a potential target for development of antiviral drugs, including nucleoside analogues (NA). However, ExoN proofreading activity of CoVs leads to their protection from several NAs. Therefore, potential platforms based on the development of efficient NAs with broad-spectrum efficacy against human CoVs should be explored. This study was then aimed to present an overview on the development of NAs-based drug repurposing for targeting SARS-CoV-2 RdRp by computational analysis. Afterwards, the clinical development of some NAs including Favipiravir, Sofosbuvir, Ribavirin, Tenofovir, and Remdesivir as potential inhibitors of RdRp, were surveyed. Overall, exploring broad-spectrum NAs as promising inhibitors of RdRp may provide useful information about the identification of potential antiviral repurposed drugs against SARS-CoV-2.

Citing Articles

Biosynthesis of Arabinoside from Sucrose and Nucleobase via a Novel Multi-Enzymatic Cascade.

Liu Y, Yang E, Zhang X, Liu X, Tang X, Wang Z Biomolecules. 2024; 14(9).

PMID: 39334873 PMC: 11430244. DOI: 10.3390/biom14091107.

Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.

Kiy R, Khoo S, Chadwick A Toxicol Res (Camb). 2024; 13(1):tfae012.

PMID: 38328743 PMC: 10848230. DOI: 10.1093/toxres/tfae012.

Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses.

Awad A, Hansen K, Del Rio D, Flores D, Barghash R, Kakkola L Biomolecules. 2023; 13(10).

PMID: 37892134 PMC: 10604481. DOI: 10.3390/biom13101452.

Current understanding of nucleoside analogs inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase.

Xu T, Zhang L Comput Struct Biotechnol J. 2023; 21:4385-4394.

PMID: 37711189 PMC: 10498173. DOI: 10.1016/j.csbj.2023.09.001.

Evolutionary safety of lethal mutagenesis driven by antiviral treatment.

Lobinska G, Pilpel Y, Nowak M PLoS Biol. 2023; 21(8):e3002214.

PMID: 37552682 PMC: 10409280. DOI: 10.1371/journal.pbio.3002214.

References

Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J . Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). PMC: 5567817. DOI: 10.1126/scitranslmed.aal3653. View

Koulgi S, Jani V, V N Uppuladinne M, Sonavane U, Joshi R . Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2. RSC Adv. 2022; 10(45):26792-26803. PMC: 9055499. DOI: 10.1039/d0ra04743k. View

Liang W, Guan W, Chen R, Wang W, Li J, Xu K . Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3):335-337. PMC: 7159000. DOI: 10.1016/S1470-2045(20)30096-6. View

Stein D, Moore K . Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy. 2001; 21(1):11-34. DOI: 10.1592/phco.21.1.11.34439. View

Smertina E, Urakova N, Strive T, Frese M . Calicivirus RNA-Dependent RNA Polymerases: Evolution, Structure, Protein Dynamics, and Function. Front Microbiol. 2019; 10:1280. PMC: 6563846. DOI: 10.3389/fmicb.2019.01280. View

Peters H, Jochmans D, de Wilde A, Posthuma C, Snijder E, Neyts J . Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorg Med Chem Lett. 2015; 25(15):2923-6. PMC: 4466200. DOI: 10.1016/j.bmcl.2015.05.039. View

Dyall J, Coleman C, Hart B, Venkataraman T, Holbrook M, Kindrachuk J . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58(8):4885-93. PMC: 4136000. DOI: 10.1128/AAC.03036-14. View

Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C . Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect. 2020; 8(6):e00674. PMC: 7596664. DOI: 10.1002/prp2.674. View

Zhu Y, Yu D, Yan H, Chong H, He Y . Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. J Virol. 2020; 94(14). PMC: 7343218. DOI: 10.1128/JVI.00635-20. View

10.

Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G . Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020; 11(1):4682. PMC: 7499305. DOI: 10.1038/s41467-020-18463-z. View

11.

Kumar R, Mishra S, Shreya , Maurya S . Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses. RSC Med Chem. 2021; 12(3):306-320. PMC: 8130609. DOI: 10.1039/d0md00318b. View

12.

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

13.

Hughes A, Barber T, Nelson M . New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect. 2008; 57(1):1-10. DOI: 10.1016/j.jinf.2008.05.006. View

14.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

15.

Shannon A, Le N, Selisko B, Eydoux C, Alvarez K, Guillemot J . Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020; 178:104793. PMC: 7151495. DOI: 10.1016/j.antiviral.2020.104793. View

16.

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

17.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

18.

Kim J, Zhang J, Cha Y, Kolitz S, Funt J, Escalante Chong R . Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19). J Transl Med. 2020; 18(1):257. PMC: 7315012. DOI: 10.1186/s12967-020-02430-9. View

19.

Jockusch S, Tao C, Li X, Anderson T, Chien M, Kumar S . A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res. 2020; 180:104857. PMC: 7299870. DOI: 10.1016/j.antiviral.2020.104857. View

20.

Barnard D, Day C, Bailey K, Heiner M, Montgomery R, Lauridsen L . Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother. 2006; 17(5):275-84. DOI: 10.1177/095632020601700505. View